CANbridge and WuXi Biologics expand rare disease partnership

Everest Medicine to commercialise Calliditas’ Nefecon in China
Credit: Plufflyman

CANbridge Pharmaceuticals has expanded its rare disease partnership with WuXi Biologics enabling it to discover, develop and commercialise four additional drug candidates in China.

The new candidates target rare genetic chronic diseases. According to the agreement, CANbridge has an exclusive regional or global rights for these therapies.

WuXi Biologics will receive upfront, milestone payments and royalties. It will also be the exclusive clinical supplier and primary commercial supplier for all these programs.

James Xue, Founder, Chairman and CEO of CANbridge Pharmaceuticals, said: “These four new drug candidates target important rare disease indications for which there are either no available treatments in China, or treatments with poor outcomes.

“These candidates are next generation therapies directed at medically-validated biological targets.

“Together with WuXi Biologics, we aim to change the rare disease landscape in China, with the submission of the first rare disease IND in China for our lead candidate later this year, and the development of new drug candidates that will bring much-needed treatments to patients with no, or few, options.

“In addition, we plan to impact the global market with these drug candidates which are developed in China.”